Skip to main content
. 2024 Jan 9;32(2):91. doi: 10.1007/s00520-023-08260-x

Table 4.

Frequency of treatment emergent adverse events

Patients with treatment emergent adverse event, n (%) Efbemalenograstim alfa Pegfilgrastim
6 mg
N = 65
80 μg/kg
N = 35
240 μg/kg
N = 67
320 μg/kg
N = 65
Any TEAE 32 (91.4) 63 (94.0) 61 (93.8) 59 (90.8)
Treatment-related TEAE 10 (28.6) 21 (31.3) 24 (36.9) 24 (36.9)
AE leading to discontinuation 1 (2.9) 1 (1.5) 2 (3.1) 3 (4.6)
Any SAE 0 1 (1.5) 1 (1.5) 4 (6.2)
Febrile neutropenia 0 0 2 (3.1) 2 (3.1)
TEAEs > 10% in any treatment group:
  Alopecia 27 (77.1) 49 (73.1) 44 (67.7) 52 (80.0)
  Nausea 17 (48.6) 22 (32.8) 23 (35.4) 28 (43.1)
  Asthenia 11 (31.4) 13 (19.4) 21 (32.3) 20 (30.8)
  Neutropenia 6 (17.1) 25 (37.3) 21 (32.3) 17 (26.2)
  Bone pain 7 (20.0) 11 (16.4) 11 (16.9) 12 (18.5)
  Fatigue 5 (14.3) 3 (19.4) 12 (18.5) 10 (15.4)
  Leukopenia 3 (8.6) 12 (17.9) 8 (12.3) 7 (10.8)
  Diarrhea 3 (8.6) 4 (6.0) 4 (6.2) 7 (10.8)
  Headache 5 (14.3) 5 (7.5) 7 (10.8) 4 (6.2)

SAE Serious adverse event; TEAE Treatment-emergent adverse event